Examining Associations Between Smartphone Use and Clinical Severity in Frontotemporal Dementia: Proof-of-Concept Study
Open accessPublished version of a preprint
The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
Background: Frontotemporal lobar degeneration (FTLD) is a leading cause of dementia in individuals aged <65 years. Several challenges to conducting in-person evaluations in FTLD illustrate an urgent need to develop remote, accessible, and low-burden assessment techniques. Studies of unobtrusive monitoring of at-home computer use in older adults with mild cognitive impairment show that declining function is reflected in reduced computer use; however, associations with smartphone use are unknown. Objective: This study aims to characterize daily trajectories in smartphone battery use, a proxy for smartphone use, and examine relationships with clinical indicators of severity in FTLD. Methods: Participants were 231 adults (mean age 52.5, SD 14.9 years; n=94, 40.7% men; n=223, 96.5% non-Hispanic White) enrolled in the Advancing Research and Treatment of Frontotemporal Lobar Degeneration (ARTFL study) and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS study) Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) Mobile App study, including 49 (21.2%) with mild neurobehavioral changes and no functional impairment (ie, prodromal FTLD), 43 (18.6%) with neurobehavioral changes and functional impairment (ie, symptomatic FTLD), and 139 (60.2%) clinically normal adults, of whom 55 (39.6%) harbored heterozygous pathogenic or likely pathogenic variants in an autosomal dominant FTLD gene. Participants completed the Clinical Dementia Rating plus National Alzheimer’s Coordinating Center Frontotemporal Lobar Degeneration Behavior and Language Domains (CDR+NACC FTLD) scale, a neuropsychological battery; the Neuropsychiatric Inventory; and brain magnetic resonance imaging. The ALLFTD Mobile App was installed on participants’ smartphones for remote, passive, and continuous monitoring of smartphone use. Battery percentage was collected every 15 minutes over an average of 28 (SD 4.2; range 14-30) days. To determine whether temporal patterns of battery percentage varied as a function of disease severity, linear mixed effects models examined linear, quadratic, and cubic effects of the time of day and their interactions with each measure of disease severity on battery percentage. Models covaried for age, sex, smartphone type, and estimated smartphone age. Results: The CDR+NACC FTLD global score interacted with time on battery percentage such that participants with prodromal or symptomatic FTLD demonstrated less change in battery percentage throughout the day (a proxy for less smartphone use) than clinically normal participants (P<.001 in both cases). Additional models showed that worse performance in all cognitive domains assessed (ie, executive functioning, memory, language, and visuospatial skills), more neuropsychiatric symptoms, and smaller brain volumes also associated with less battery use throughout the day (P<.001 in all cases). Conclusions: These findings support a proof of concept that passively collected data about smartphone use behaviors associate with clinical impairment in FTLD. This work underscores the need for future studies to develop and validate passive digital markers sensitive to longitudinal clinical decline across neurodegenerative diseases, with potential to enhance real-world monitoring of neurobehavioral change.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, in the ALLFTD cohort, participants with prodromal or symptomatic frontotemporal lobar degeneration (FTLD) demonstrated less change in battery percentage (a proxy for less phone usage) than those without symptoms, and less battery use was associated with worse cognitive test results, more neuropsychiatric symptoms, and smaller brain volumes. 64”
From Developing digital health technologies for frontotemporal degeneration (2025) · cites this paper as [64]
The cited source says what the claim attributes to it.
In the citing paper
“Preliminary studies of the ALLFTD mApp suggest that passively collected data about smartphone use behaviors are associated with clinical functioning in FTD.”
From Developing digital health technologies for frontotemporal degeneration (2025) · cites this paper as [64]
The cited source says what the claim attributes to it.
In the citing paper
“For example, in the ALLFTD cohort, participants with prodromal or symptomatic frontotemporal lobar degeneration (FTLD) demonstrated less change in battery percentage (a proxy for less phone usage) than those without symptoms, and less battery use was associated with worse cognitive test results, more neuropsychiatric symptoms, and smaller brain volumes. 64”
From Developing digital health technologies for frontotemporal degeneration (2025) · cites this paper as [64]
The cited source says what the claim attributes to it.
In the citing paper
“For example, in the ALLFTD cohort, participants with prodromal or symptomatic frontotemporal lobar degeneration (FTLD) demonstrated less change in battery percentage (a proxy for less phone usage) than those without symptoms, and less battery use was associated with worse cognitive test results, more neuropsychiatric symptoms, and smaller brain volumes. 64”
From Developing digital health technologies for frontotemporal degeneration (2025) · cites this paper as [64]
The cited source says what the claim attributes to it.
In the citing paper
“For example, in the ALLFTD cohort, participants with prodromal or symptomatic frontotemporal lobar degeneration (FTLD) demonstrated less change in battery percentage (a proxy for less phone usage) than those without symptoms, and less battery use was associated with worse cognitive test results, more neuropsychiatric symptoms, and smaller brain volumes. 64”
From Developing digital health technologies for frontotemporal degeneration (2025) · cites this paper as [64]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678 · cited 1×
“As we enter the era of disease-modifying treatments for neurodegenerative diseases, early detection is critical to identify those eligible for clinical trial participation and early treatment to slow or stop disease progression [8-10].”
BackgroundSensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221 · cited 1×
“…symptoms at the prodromal stage (ie, no functional impairment) or fully symptomatic (ie, with functional impairment) level of severity that are consistent with an FTLD-related clinical phenotype per conference consensus with neurologists and neuropsychologists following published criteria [32-35].”
BackgroundSelf-citationClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Self-citationAppelhof, B., Bakker, C., Van Duinen-van den Ijssel, J. C. L., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., de Vugt, M. E., Zuidema, S. U., & Koopmans, R. T. C. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477087 · Cited by 2,760
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Höglinger, G. U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K. A., Lang, A. E., Mollenhauer, B., Müller, U., Nilsson, C., Whitwell, J. L., et al. (2017) · Movement Disorders · doi:10.1002/mds.26987 · Cited by 2,359
Self-citationQualitative Assessment of Verbal Fluency Performance in Frontotemporal Dementia
van den Berg, E., Jiskoot, L. C., Grosveld, M. J. H., van Swieten, J. C., & Papma, J. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477538 · Cited by 2,046
Validation of the NPI-Q, a Brief Clinical Form of the Neuropsychiatric Inventory
Kaufer, D., Cummings, J. L., Ketchel, P., Smith, V. M., MacMillan, A., Shelley, T., López, O. L., & DeKosky, S. T. (2000) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.12.2.233 · Cited by 1,973 · cited 1×
“Informants also completed the Neuropsychiatric Inventory [47] to assess the presence and severity of neuropsychiatric symptoms in participants.”
Criteria for the diagnosis of corticobasal degeneration
Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0fd1 · Cited by 1,904 · cited 1×
“…symptoms at the prodromal stage (ie, no functional impairment) or fully symptomatic (ie, with functional impairment) level of severity that are consistent with an FTLD-related clinical phenotype per conference consensus with neurologists and neuropsychologists following published criteria [32-35].”
BackgroundSelf-citationMorris, J. C. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004870 · Cited by 1,641 · cited 1×
“…the level of cognitive and everyday functioning impairment using the CDR+NACC FTLD scale [38], which is a validated, modified version of the CDR [39] that has higher sensitivity to functional impairment in FTLD. CDR+NACC FTLD global scores [40] were used to categorize participants into disease…”
Method
Research works printed but not linked: 2
- Workshop on applying digital technology for early diagnosis and monitoring of Alzheimer’s disease and related dementiasNational Institutes of Health National Institute on Aging2024-04-03https://www.nia.nih.gov/research/dn/workshops/workshop-applying-digital-technology-early-diagnosis-and-monitoring
- Li, H, 2024, arXiv. Preprint posted online January 12, 2018
Cited by
A meta-analysis of technology use and cognitive aging
Benge, J. F., & Scullin, M. K. (2025) · Nature Human Behaviour · doi:10.1038/s41562-025-02159-9 · Cited by 114
Shaik, M. A., Anik, F. I., Hasan, M. M., Chakravarty, S., Ramos, M. D., Rahman, M. A., Ahamed, S. I., & Sakib, N. (2025) · JMIR Aging · doi:10.2196/69175 · Cited by 37
“Conditions such as vascular dementia [22,23], Lewy body dementia [24], and frontotemporal dementia [25] share overlapping symptoms [26,27], including cognitive decline, behavior changes, and mobility issues, which can similarly benefit from remote monitoring interventions.”
Hackett, K., Xu, S., McKniff, M., Paglia, L., Barnett, I., & Giovannetti, T. (2024) · JMIR Human Factors · doi:10.2196/59974 · Cited by 33
Developing digital health technologies for frontotemporal degeneration
Nevler, N., Niehoff, D., Gleixner, A. M., Dodge, S., Vogel, A. P., Hill, D. L., Ducharme, S., Staffaroni, A. M., Yunusova, Y., Au, R., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70082 · Cited by 7
Self-citationReview of Artificial Intelligence for Clinical Use in Alzheimer's Disease and Related Dementias
Breithaupt, A. G., Tang, A., Paolillo, E. W., Bibars, M., Johnson, E. C. B., Saloner, R., Possin, K. L., Windon, C. C., Hill-Jarrett, T. G., Giorgio, J., et al. (2026) · Seminars in Neurology · doi:10.1055/a-2744-9871 · Cited by 6
Self-citationZawada, S. J., Acosta, J., Collins, C., Dumitrașcu, O., Harahsheh, E. Y., Hagen, C. E., Ganjizadeh, A., Mahmoudi, E., Erickson, B. J., & Demaerschalk, B. M. (2025) · medRxiv · doi:10.1101/2025.01.23.25320624
“Another challenge documented was battery drain associated with GPS streaming and routine OS software updates; yet, emerging research suggests battery drain may also be a digital biomarker of cognitive function [45].”
Brotherhood, E., Baou, C. E., Fearn, C., Hayes, O. S., Zimmermann, N., Tsipa, A., Crutch, S. J., & Stott, J. C. H. (2025) · doi:10.2196/preprints.85863
Brotherhood, E., Baou, C. E., Fearn, C., Hayes, O. S., Zimmermann, N., Tsipa, A., Crutch, S. J., & Stott, J. C. H. (2026) · JMIR Aging · doi:10.2196/85863
“FTD populations, for example, exhibit lower smartphone battery usage relative to clinically neurotypical controls [43], which may necessitate other means of presenting health and well-being information for these groups that seem not to engage with smartphone interaction.”
Older adults’ views of passive smartphone monitoring for dementia risk: a multi-method analysis
Hackett, K., Wurtz, H., Zhu, C. W., Loizos, M., Berroa, F., Espinoza, H. R., Federman, A. D., & Sano, M. (2026) · Innovation in Aging · doi:10.1093/geroni/igag034
Mindt, M. R., Savin, M. J., Guzman, V., Arentoft, A., Barragan, E. V., Cubbellotti, S., Heuer, H. W., Germano, K. K., Rosen, H. J., Cho, S. J., et al. (2026) · medRxiv · doi:10.64898/2026.06.01.26354636
Self-citationDini, M., Maida, E., Lavorgna, L., Buizer, A. I., Fanciulli, A., Medijainen, K., Nonnekes, J. H., Ortigoza‐Escobar, J. D., Salamon, A., Timmann, D., et al. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13911-0
Campbell, L. M., Hackett, K., Paolillo, E. W., Schultheis, M. T., & Chaytor, N. S. (2026) · Oxford University Press eBooks · doi:10.1093/9780197814116.003.0009
Self-citationDigital health technologies in frontotemporal dementia: A scoping review
de Boer, L., Aro, O. A., Seelaar, H., Jiskoot, L. C., & Poos, J. M. (2026) · Digital Health · doi:10.1177/20552076261483445
Smartphone Passive Digital Phenotyping in Frontotemporal Lobar DegenerationPreprint
Paolillo, E. W., Dhanam, S., Taylor, J. C., Sanderson‐Cimino, M. E., Fregly, R., Saloner, R., Casaletto, K. B., Kramer, J. H., Miller, B. L., Seeley, W. W., et al. (2026) · medRxiv · doi:10.64898/2026.09.18.26363439
Self-citationZhang, Y., Shi, Y., Yamamoto, J., & Kubota, N. (2026) · JMIR Serious Games · doi:10.2196/104623
Prieto, S., Thompson, L. I., Split, M., Rooney, C. N., Ross, D., Sunderaraman, P., Vito, A. N. D., Roque, N. A., Felt, J. M., Sliwinski, M. J., et al. (2026) · Frontiers in Digital Health · doi:10.3389/fdgth.2026.1878732
“Prior work suggests device and OS variability can affect timing precision in mobile assessments (61), and future studies should consider documenting and controlling for this.”
Metadata
- Authors
- Paolillo, E. W., Casaletto, K. B., Clark, A. L., Taylor, J. C., Heuer, H. W., Wise, A. B., Dhanam, S., Sanderson-Cimino, M., Saloner, R., Kramer, J. H., Kornak, J., Kremers, W., Forsberg, L., Appleby, B., Bayram, E., Bozoki, A., Brushaber, D., Darby, R. R., Day, G. S., Dickerson, B. C., Domoto-Reilly, K., Elahi, F., Fields, J. A., Ghoshal, N., Graff-Radford, N., G H Hall, M., Honig, L. S., Huey, E. D., Lapid, M. I., Litvan, I., Mackenzie, I. R., Masdeu, J. C., Mendez, M. F., Mester, C., Miyagawa, T., Naasan, G., Pascual, B., Pressman, P., Ramos, E. M., Rankin, K. P., Rexach, J., Rojas, J. C., VandeVrede, L., Wong, B., Wszolek, Z. K., Boeve, B. F., Rosen, H. J., Boxer, A. L., Staffaroni, A. M., & ALLFTD Consortium
- Affiliations
- University of California, San Francisco (US)
- Mayo Clinic (US)
- Case Western Reserve University (US)
- University of California San Diego (US)
- University of North Carolina at Chapel Hill (US)
- Vanderbilt University (US)
- Mayo Clinic in Florida (US)
- Harvard University (US)
- James J. Peters VA Medical Center (US)
- Washington University in St. Louis (US)
- Columbia University (US)
- Brown University (US)
- University of British Columbia (CA)
- Weill Cornell Medicine (US)
- University of California, Los Angeles (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Colorado Anschutz (US)
- Corresponding author
- Paolillo, Emily W
- ORCID
- Paolillo, Emily W
- Casaletto, Kaitlin B
- Clark, Annie L
- Taylor, Jack C
- Heuer, Hilary W
- Wise, Amy B
- Dhanam, Sreya
- Sanderson-Cimino, Mark
- Saloner, Rowan
- Kramer, Joel H
- Kornak, John
- Kremers, Walter
- Forsberg, Leah
- Appleby, Brian
- Bayram, Ece
- Bozoki, Andrea
- Brushaber, Danielle
- Darby, R Ryan
- Day, Gregory S
- Dickerson, Bradford C
- Domoto-Reilly, Kimiko
- Elahi, Fanny
- Fields, Julie A
- Ghoshal, Nupur
- Graff-Radford, Neill
- G H Hall, Matthew
- Honig, Lawrence S
- Huey, Edward D
- Lapid, Maria I
- Litvan, Irene
- Mackenzie, Ian R
- Masdeu, Joseph C
- Mendez, Mario F
- Mester, Carly
- Miyagawa, Toji
- Naasan, Georges
- Pascual, Belen
- Pressman, Peter
- Ramos, Eliana Marisa
- Rankin, Katherine P
- Rexach, Jessica
- Rojas, Julio C
- VandeVrede, Lawren
- Wong, Bonnie
- Wszolek, Zbigniew K
- Boeve, Bradley F
- Rosen, Howard J
- Boxer, Adam L
- Staffaroni, Adam M
- Venue
- JMIR Aging
- Publisher
- JMIR Publications Inc.
- Published
- 2024-06-26
- Volume
- 7
- Pages
- e52831
- ISSN
- 2561-7605 (ISSN-L)
- PMC
- PMC11237775
- OpenAlex
- W4400039427
- Cited by
- 16
- References
- 75
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 1
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- JMIR Aging (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UNC Libraries
- Funders
- U.S. Department of Veterans Affairs (IK2CX002180)
- Alzheimer's Association (AARF-23-1145318, AARF-22, AARF-22-974065)
- Association for Frontotemporal Degeneration
- Eli Lilly and Company
- Pfizer
- Biogen
- University of Southern California
- University of Pennsylvania
- Emory University
- Northwestern University
- Cleveland Clinic
- University of Washington
- Johns Hopkins University
- CurePSP
- Demensförbundet
- Horizon Pharmaceuticals
- Rainwater Charitable Foundation
- University of Toronto
- Eisai
- Universiteit Antwerpen
- National Institutes of Health (1r21ns114764-01a1, AG016976, AG019724, AG021886, AG063911, AG045390, AG058233, NS050915, AG032306, NS092089)
- Centers for Disease Control and Prevention
- University of California, San Diego
- University of California, San Francisco (AG019724)
- National Institute on Aging (R01AG058233, K23AG059888, U01AG057195, U01AG016976, K23AG061253, U01AG045390, R01AG032306, K23AG064029, RF1AG077557, RF1AG032289, U19AG032438, K24AG045333, R01AG038791, U19AG063911, R01AG077557, P01AG019724, P30AG062422, K23AG073514, P30AG066514, P30AG062677, P30AG066509, R01AG032289, U24AG021886)
- National Institute of Neurological Disorders and Stroke (R21 NS114764, K08NS105916, RF1NS050915, R56NS050915, U54NS092089, U01NS120901, R25NS098999, R01NS050915, U01NS100610)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Social Sciences › Psychology › Clinical Psychology › Historical and Modern Theater Studies
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- frontotemporal lobar degeneration, frontotemporal dementia, smartphone use, remote monitoring, disease severity, familial frontotemporal lobar degeneration, neurobehavioral symptoms, neuropsychiatric symptoms, neuropsychological assessment, mobile health, non-intrusive monitoring
- MeSH terms
- Smartphone, Proof of Concept Study, Adult, Aged, Female, Humans, Longitudinal Studies, Male, Middle Aged, Neuropsychological Tests, Severity of Illness Index, Frontotemporal Dementia, Mobile Applications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.